BR112022021374A2 - Constructo de dna, genes da proteína s de sars-cov-2, vetor, peptídeo sinal, composição imunogênica e seu método de preparação e vacina - Google Patents
Constructo de dna, genes da proteína s de sars-cov-2, vetor, peptídeo sinal, composição imunogênica e seu método de preparação e vacinaInfo
- Publication number
- BR112022021374A2 BR112022021374A2 BR112022021374A BR112022021374A BR112022021374A2 BR 112022021374 A2 BR112022021374 A2 BR 112022021374A2 BR 112022021374 A BR112022021374 A BR 112022021374A BR 112022021374 A BR112022021374 A BR 112022021374A BR 112022021374 A2 BR112022021374 A2 BR 112022021374A2
- Authority
- BR
- Brazil
- Prior art keywords
- dna construct
- signal peptide
- vector
- vaccine
- preparation
- Prior art date
Links
- 108010076504 Protein Sorting Signals Proteins 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 230000002163 immunogen Effects 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 title abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 2
- 229940096437 Protein S Drugs 0.000 abstract 2
- 101150027674 S1 gene Proteins 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 108010066124 Protein S Proteins 0.000 abstract 1
- 101150010882 S gene Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
CONSTRUCTO DE DNA, GENES DA PROTEÍNA S DE SARS-COV-2, VETOR, PEPTÍDEO SINAL, COMPOSIÇÃO IMUNOGÊNICA E SEU MÉTODO DE PREPARAÇÃO E VACINA. A presente invenção fornece um constructo de DNA compreendendo o gene S ou a região do gene S1 da proteína da espícula-S de 2019-nCoV. O constructo de DNA da presente invenção compreende um vetor de DNA de plasmídeo que carregando o gene S ou a região do gene S1 da proteína da espícula-S de 2019-nCoV. O vetor pode compreender adicionalmente um gene que codifica o peptídeo sinal IgE ou um gene que codifica o peptídeo sinal t-PA. O constructo de DNA de acordo com a presente invenção é usado adicionalmente na preparação de uma composição imunogênica ou uma vacina para tratar ou prevenir o coronavírus ou suas doenças relacionadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202021017410 | 2020-04-23 | ||
| PCT/IB2021/053321 WO2021214703A1 (en) | 2020-04-23 | 2021-04-22 | A vaccine against sars-cov-2 and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022021374A2 true BR112022021374A2 (pt) | 2023-01-10 |
Family
ID=78270337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022021374A BR112022021374A2 (pt) | 2020-04-23 | 2021-04-22 | Constructo de dna, genes da proteína s de sars-cov-2, vetor, peptídeo sinal, composição imunogênica e seu método de preparação e vacina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230174588A1 (pt) |
| EP (1) | EP4138908A1 (pt) |
| JP (1) | JP2023523423A (pt) |
| KR (1) | KR20230005265A (pt) |
| CN (1) | CN116075319A (pt) |
| AR (1) | AR121910A1 (pt) |
| BR (1) | BR112022021374A2 (pt) |
| MX (1) | MX2022013028A (pt) |
| TW (1) | TW202206598A (pt) |
| WO (1) | WO2021214703A1 (pt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| CN115335390A (zh) * | 2022-01-10 | 2022-11-11 | 广州市锐博生物科技有限公司 | 基于SARS-CoV-2的S蛋白的疫苗和组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080642B2 (en) * | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
| CN1977045A (zh) * | 2003-08-04 | 2007-06-06 | 马萨诸塞大学 | Sars核酸,蛋白质,疫苗以及它们的用途 |
| US10960070B2 (en) * | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| CN110951756B (zh) * | 2020-02-23 | 2020-08-04 | 广州恩宝生物医药科技有限公司 | 表达SARS-CoV-2病毒抗原肽的核酸序列及其应用 |
-
2021
- 2021-04-22 WO PCT/IB2021/053321 patent/WO2021214703A1/en active Search and Examination
- 2021-04-22 KR KR1020227040871A patent/KR20230005265A/ko unknown
- 2021-04-22 TW TW110114524A patent/TW202206598A/zh unknown
- 2021-04-22 MX MX2022013028A patent/MX2022013028A/es unknown
- 2021-04-22 EP EP21793685.5A patent/EP4138908A1/en not_active Withdrawn
- 2021-04-22 BR BR112022021374A patent/BR112022021374A2/pt not_active Application Discontinuation
- 2021-04-22 US US17/920,158 patent/US20230174588A1/en active Pending
- 2021-04-22 CN CN202180043085.XA patent/CN116075319A/zh active Pending
- 2021-04-22 AR ARP210101078A patent/AR121910A1/es unknown
- 2021-04-22 JP JP2022564444A patent/JP2023523423A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4138908A1 (en) | 2023-03-01 |
| AR121910A1 (es) | 2022-07-20 |
| US20230174588A1 (en) | 2023-06-08 |
| MX2022013028A (es) | 2022-11-30 |
| WO2021214703A1 (en) | 2021-10-28 |
| CN116075319A (zh) | 2023-05-05 |
| JP2023523423A (ja) | 2023-06-05 |
| TW202206598A (zh) | 2022-02-16 |
| KR20230005265A (ko) | 2023-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2866899T3 (es) | Neurotoxinas quiméricas | |
| BR112022021374A2 (pt) | Constructo de dna, genes da proteína s de sars-cov-2, vetor, peptídeo sinal, composição imunogênica e seu método de preparação e vacina | |
| Jang et al. | EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro | |
| US9243301B2 (en) | Fusion proteins | |
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| Sohag et al. | Revisiting potential druggable targets against SARS‐CoV‐2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review | |
| BR112022014884A2 (pt) | Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave | |
| BR112022022456A2 (pt) | Proteínas de ligação de repetição de anquirina e seus usos | |
| BR112022019501A2 (pt) | Construção de rna auto-amplificante (sarna), sarna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de sarna, construção de sarna e vacina | |
| JP2019004909A (ja) | 融合タンパク質および疼痛を治療、予防または緩和するための方法 | |
| BR112022022503A2 (pt) | Anticorpos neutralizantes que se ligam à proteína s de sars-cov-2 | |
| WO2020127532A3 (en) | Rna encoding a protein | |
| Faist et al. | Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier | |
| Plemper et al. | Structural features of paramyxovirus F protein required for fusion initiation | |
| Wu et al. | The antiviral protein viperin interacts with the viral N protein to inhibit proliferation of porcine epidemic diarrhea virus | |
| BR112022026580A2 (pt) | Composições e métodos para induzir uma resposta imune contra coronavírus | |
| CO2023009633A2 (es) | Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal | |
| Min et al. | Restoration of cellular proliferation and characteristics of human tenocytes by vitamin D | |
| Mahmud et al. | Bacillus pumilus ribonuclease rescues mice infected by double-stranded RNA-containing reovirus serotype 1 | |
| Li et al. | Molecular cloning and functional characterization of duck DDX41 | |
| JP2023527950A (ja) | Ｎ－置換ピリジルベンズイソセラゾロン化合物の使用 | |
| BR112021026292A2 (pt) | Cistationina beta sintase peguilada para terapia enzimática para tratamento de homocistinúria | |
| BR112023005623A2 (pt) | Composições e métodos para modular simultaneamente expressão de genes | |
| Li et al. | Host protein, HSP90β, antagonizes IFN-β signaling pathway and facilitates the proliferation of encephalomyocarditis virus in vitro |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |